We are very excited to have just posted the full preprint of our new ME/CFS immune profiling paper on BioRxiv, which will continue to be updated following reviewer comment and peer-review. In this detailed study, we analyzed the immunological differences between ME/CFS patients and healthy controls within a large cohort and found several major differences in T cell subset frequencies and functions between the two groups.
ME/CFS is a complex and heterogeneous chronic condition that is highly debilitating and often characterized by persistent, unexplained fatigue not alleviated by rest, muscle and joint pain, sleep problems, and post-exertional malaise (PEM). There is no clear diagnostic test for the disease, so diagnosis is based largely on clinical symptoms. It’s thought that around 90% of people with ME/CFS have not been diagnosed, and up to 2.5 million Americans suffer from it, with many more suffering worldwide. This costs the US economy an estimated $17 to $24 billion annually in medical bills and lost income.